Disclosed herein is a recombinant antibody exhibiting binding affinity and/or neutralizing activity to porcine epidemic diarrhea virus (PEDV). According to some embodiments of the present disclosure, the PEDV is genotype 1 (G1) or genotype 2b (G2b) PEDV. Also disclosed herein are methods of diagnosing and treating PEDV infection by use of the present recombinant antibody.

In alternative embodiments, provided are methods for treating, ameliorating, decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from, or preventing an infection by administration of an antibiotic and/or an anti-viral drugs and a vaccine directed to a causative agent of the infection and/or an attenuated and/or a live, viable or infectious causative agent of the infection. In alternative embodiments, the infection is bacterial or viral. In alternative embodiments, the viral infection is a coronavirus infection such a Covid-19 infection. In alternative embodiments, methods as provide herein prevent or decrease the prevalence or severity of “vaccine breakthrough infections” after vaccination, where external mutants of COVID-19 infect patients in spite of the fact that they have undergone immunization, for example, to prevent a mutant or variant COVID-19 infection. In alternative embodiments, an antiviral combination administered in coordination with a vaccine comprises PF-07321332 or PAXLOVID™ and/or ritonavir, or ivermectin, doxycycline and a zinc or a zinc salt. In alternative embodiments, methods as provided herein are used to prevent in vivo mutations of such mutant infectious agent to enhance the efficacy of an administered vaccination; in other words, methods as provided herein are used to prevent in vivo replication of an acquired viral mutant or variant infectious agent, and thus also prevents ongoing mutations of the viral infectious agent because using the combination antiviral co-therapy where there is no replication of infectious agent and so there is no possible further mutation of the infectious agent.

The present invention relates to methods for obtaining a substantially pure population of pluripotent stem cell-derived airway basal-like cells. It also relates to a method of obtaining an in vitro pluripotent stem cell-derived airway epithelium model, utilising the pluripotent stem cell-derived airway basal-like cells. The invention further relates to an in vitro airway epithelial model, or lung model, which can be used for disease modelling and/or drug screening and in particular to an in vitro model for SARS-CoV-2 infection and for screening for agents effective against infection with SARS-CoV-2 i.e. COVID-19 and methods of using the same.

Methods of treating a subject suffering from COVID-19 are provided. Aspects of the methods including administering to the subject an effective amount of an inhibitor of CCR5/CCL5 interaction, such as a CCR5 antagonist. Also provided are methods of assessing severity of a disease involving hypercytokinemia, such as COVID-19, by determining the level of CCL5/RANTES in a subject, as well as compositions for use in such methods.

The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.

The present invention provides a novel coronavirus duplex detection kit. Specifically, the present invention discloses a kit and method for multiplex detection of novel coronavirus 2019-nCoV nucleic acid, which can simultaneously detect two nucleic acid targets of the novel coronavirus 2019-nCoV and possess extremely high sensitivity and specificity, and significantly improve the accuracy of virus identification.

An antiviral fabric including a fabric and an antiviral coating layer which is provided in the fabric and which includes an antiviral fusion protein having an antiviral motif bound to an adhesive protein. The antiviral fabric has excellent processability that enables simple implementation of the antiviral coating layer even on the curved surface of a fiber, the porous surface of a fabric, or a recessed or protruding surface. In addition, the antiviral fabric can have activity persistence that enable maintenance of antiviral activity for a long time without losing the same according to a condition during preparation, storage, use and washing, while having adhesion persistence that enables the maintenance of an adhesive state for a long time after the antiviral coating layer is formed on the surface thereof, and thus can be widely applied to various articles for which fabric is used.

The present invention provides pharmaceutical compositions of a hydroxyl halide of a peptide and methods of use of these compositions in treating viral infections caused by coronavirus and influenza viruses.

The present invention discloses novel attenuated bovine coronavirus isolates, compositions comprising these isolate, and methods of using such compositions in vaccines, including in live vaccines. The present invention further discloses the administration of such vaccines, including the intranasal administration of such vaccines, to aid in the prevention of respiratory disease caused by bovine coronavirus.

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.